We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MIMETAS Receives Funding For Kidney-On-A-Chip

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "MIMETAS Receives Funding For Kidney-On-A-Chip "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

The organ-on-a-chip company MIMETAS has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. MIMETAS will collaborate in a consortium with Radboudumc (Nijmegen, The Netherlands) and FHNW (Basel, Switzerland). A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions has selected MIMETAS’ solution from a strong line-up of competing technologies.

The funding is awarded in the context of the NephroTube CRACK IT Challenge to support development of a microfluidic renal model, predicting renal toxicity during pre-clinical development. The consortium will use the funds to develop, analyze and validate a high-throughput kidney-on-a-chip model by combining MIMETAS’ OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™. The resulting model will be used to detect renal tubular injury observed in drug-induced nephrotoxicity. The model’s early prediction of nephrotoxicity will help to reduce animal experiments.